Trial Profile
A Methodology Study To Evaluate The Acute Effects Of Donepezil On Regional Cerebral Perfusion And Cognition In Subjects With Amnestic Mci And Mild Alzheimer's Disease.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Pharmacodynamics
- Sponsors Pfizer
- 11 Sep 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 07 Jul 2012 Planned end date changed from 1 Sep 2012 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.